Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SIK1 | P57059 | 1/20 | 0.42 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415699 | 0.91 | FGFR1 (0.54) | FGFR1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL30033882 | 0.85 | FGFR1 (0.65) | FGFR1ALDH1A1HPGD | |
| SCHEMBL23675204 | 0.85 | FGFR1 (0.65) | FGFR1ALDH1A1HPGD | |
| SCHEMBL7975682 | 0.84 | FGFR1 (0.67) | FGFR1ALDH1A1 | |
| SCHEMBL28722636 | 0.84 | FGFR1 (0.63) | FGFR1ALDH1A1HPGD | |
| SCHEMBL23725339 | 0.83 | MEN1 (0.68) | FGFR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2642021 | 0.83 | FGFR1 (0.65) | FGFR1ALDH1A1 | |
| SCHEMBL2654246 | 0.83 | FGFR1 (0.61) | FGFR1ALDH1A1HPGD | |
| SCHEMBL2650321 | 0.81 | FGFR1 (0.59) | FGFR1ALDH1A1HPGD | |
| SCHEMBL2648829 | 0.80 | FGFR1 (0.44) | FGFR1MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288418-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2012-10-16 | — | — | US | disclosed |
| US-8288418-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2012-10-16 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | disclosed |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | disclosed |
| EP-2319837-A1 | Benzimidazole derivatives and their use for modulating the GABAa receptor complex | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2011047315-A1 | SUBSITITUTED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-7902230-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-03-08 | — | — | US | disclosed |
| US-7902230-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-03-08 | — | — | US | disclosed |
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | disclosed |
| EP-0821682-B1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2000-07-19 | — | — | EP | disclosed |
| US-5922725-A | Benzimidazole compounds and their use as modulators of the GABAA receptor complex | NEUROSEARCH A/S (DK) | 1999-07-13 | — | — | US | disclosed |
| EP-0821682-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033191-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885MEN1 4310/4885KMT2A 1828/4885 |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885MEN1 4310/4885KMT2A 1828/4885 |
| US-20110172280-A1 | Substituted Benzimidazoles | GABRA5, GABRB1, GABRA4 | FGFR1 1006/4885MEN1 3707/4885KMT2A 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.